Of Mice and Melanoma: PDX System for Modeling Personalized Medicine

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2016 Feb 5

PMID 26842234

Citations 6

Authors

Edward J Hartsough

Andrew E Aplin

Affiliations

Soon will be listed here.

Abstract

Targeted therapies have advanced the treatment options for cutaneous melanoma, but many patients will progress on drug. Patient-derived xenografts (PDX) can be used to recapitulate therapy-resistant tumors. Furthermore, PDX modeling can be utilized in combination with targeted sequencing and phosphoproteomic platforms, providing preclinical basis for second-line targeted inhibitor strategies. See related article by Krepler et al., p. 1592.

Citing Articles

Patient-derived tumor xenograft animal model of gastric cancer in precision chemotherapy.

Zhang Y, Yang Y, Zhou J, Yu Q, Chen L, Zhao L Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39969603 DOI: 10.1007/s00210-025-03903-8.

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.

Florenes V, Flem-Karlsen K, McFadden E, Bergheim I, Nygaard V, Nygard V Transl Oncol. 2019; 12(7):951-958.

PMID: 31096111 PMC: 6520638. DOI: 10.1016/j.tranon.2019.04.001.

Cutaneous Melanoma-A Long Road from Experimental Models to Clinical Outcome: A Review.

Coricovac D, Dehelean C, Moaca E, Pinzaru I, Bratu T, Navolan D Int J Mol Sci. 2018; 19(6).

PMID: 29795011 PMC: 6032347. DOI: 10.3390/ijms19061566.

Biodynamic digital holography of chemoresistance in a pre-clinical trial of canine B-cell lymphoma.

Choi H, Li Z, Sun H, Merrill D, Turek J, Childress M Biomed Opt Express. 2018; 9(5):2214-2228.

PMID: 29760982 PMC: 5946783. DOI: 10.1364/BOE.9.002214.

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.

Barutello G, Rolih V, Arigoni M, Tarone L, Conti L, Quaglino E Int J Mol Sci. 2018; 19(3).

PMID: 29534457 PMC: 5877660. DOI: 10.3390/ijms19030799.

References

McDermott S, Eppert K, Lechman E, Doedens M, Dick J . Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010; 116(2):193-200. DOI: 10.1182/blood-2010-02-271841. View

Chan M, Haydu L, Menzies A, Azer M, Klein O, Lyle M . The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition. Cancer. 2014; 120(20):3142-53. DOI: 10.1002/cncr.28851. View

Krepler C, Xiao M, Sproesser K, Brafford P, Shannan B, Beqiri M . Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clin Cancer Res. 2015; 22(7):1592-602. PMC: 4818716. DOI: 10.1158/1078-0432.CCR-15-1762. View

Seifert H, Hirata E, Gore M, Khabra K, Messiou C, Larkin J . Extrinsic factors can mediate resistance to BRAF inhibition in central nervous system melanoma metastases. Pigment Cell Melanoma Res. 2015; 29(1):92-100. PMC: 4737278. DOI: 10.1111/pcmr.12424. View

Cho J, Robinson J, Arave R, Burnett W, Kircher D, Chen G . AKT1 Activation Promotes Development of Melanoma Metastases. Cell Rep. 2015; 13(5):898-905. PMC: 4646731. DOI: 10.1016/j.celrep.2015.09.057. View

Ladanyi A . Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 2015; 28(5):490-500. DOI: 10.1111/pcmr.12371. View

Cooper Z, Juneja V, Sage P, Frederick D, Piris A, Mitra D . Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res. 2014; 2(7):643-54. PMC: 4097121. DOI: 10.1158/2326-6066.CIR-13-0215. View

Basile K, Abel E, Dadpey N, Hartsough E, Fortina P, Aplin A . In vivo MAPK reporting reveals the heterogeneity in tumoral selection of resistance to RAF inhibitors. Cancer Res. 2013; 73(23):7101-10. PMC: 3851924. DOI: 10.1158/0008-5472.CAN-13-1628. View

Hartsough E, Basile K, Aplin A . Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res. 2014; 12(5):795-802. PMC: 4020954. DOI: 10.1158/1541-7786.MCR-13-0581. View

10.

Derose Y, Wang G, Lin Y, Bernard P, Buys S, Ebbert M . Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17(11):1514-20. PMC: 3553601. DOI: 10.1038/nm.2454. View

11.

Seghers A, Wilgenhof S, Lebbe C, Neyns B . Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012; 22(6):466-72. DOI: 10.1097/CMR.0b013e3283541541. View

12.

Schiewer M, Goodwin J, Han S, Brenner J, Augello M, Dean J . Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012; 2(12):1134-49. PMC: 3519969. DOI: 10.1158/2159-8290.CD-12-0120. View

13.

Das Thakur M, Salangsang F, Landman A, Sellers W, Pryer N, Levesque M . Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013; 494(7436):251-5. PMC: 3930354. DOI: 10.1038/nature11814. View